U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C11H13NO3
Molecular Weight 207.2258
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDRASTININE

SMILES

CN1CCC2=C(C=C3OCOC3=C2)C1O

InChI

InChIKey=YOJQZPVUNUQTDF-UHFFFAOYSA-N
InChI=1S/C11H13NO3/c1-12-3-2-7-4-9-10(15-6-14-9)5-8(7)11(12)13/h4-5,11,13H,2-3,6H2,1H3

HIDE SMILES / InChI

Molecular Formula C11H13NO3
Molecular Weight 207.2258
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Hydrastinine is a synthetic alkaloid prepared by various processes from either hydrastine, berberine, or narcotine. It exerts a strong stimulating action on the uterus of all species studied, including human. Hydrastinine and the closely related alkaloid cotarnine have been employed as hemostatics, particularly in abnormal uterine conditions. In the non-pregnant animal, hydrastinine in doses of 10 mg. depressed both tonus and activity, even after the section of the hypogastric. In the pregnant cat, it caused the uterus to contract. A stimulant action was also noted in the non-pregnant animal if nicotine were administered prior to hydrastinine. The rabbit uterus in situ was strongly contracted. Laidlaw believed that hydrastinine acted on the uterus both directly on the smooth muscle and also through its sympathetic innervation. Repeated administration of large doses for a period of time resulted in greatly increased amplitude of contractions which persisted after removal of the drug. The drug was patented by Bayer as a haemostatic drug during the 1910s.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Overview

CYP3A4CYP2C9CYP2D6hERG

Drug as perpetrator​

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Rat LD50=104 mg/kg
Route of Administration: Intraperitoneal
In Vitro Use Guide
PC12 cells were maintained routinely in RPMI 1640 medium supplemented with 10 % heat-inactivated horse serum and 5 % fetal calf serum plus 100 units/ml penicillin and 100 μg/ml streptomycin at 37 °C. PC12 cells (ca. 1 × 10^5 cells/cm2) were treated with hydrastine derivatives (5 - 40 μM) into the medium and then were incubated for 6 (-48) h in the presence of the hydrastine derivatives. The cells (ca. 1.5 - 2 × 10^5cells/cm2) were harvested with phosphate buffered saline and then were centrifuged. The cell pellets were used for the measurement of dopamine content, and the intracellular TH and AADC activities.
Substance Class Chemical
Record UNII
V1I0L48X6E
Record Status Validated (UNII)
Record Version